# US 2016/0251622 A1 · Post-natal hematopoeitic endothelial cells and their isolation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251622 A1
- Document ID: US20160251622A1
- Status: Published application
- Kind: A1
- Application number: 15/032,287
- Filed: 2014-11-13
- Published: 2016-09-01
- Earliest claimed: 2013-11-13
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Vladislav M. SANDLER
- Web page: https://patentgrep.com/patent/US20160251622A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C12N 5/069: {Vascular Endothelial cells}
- G01N 33/56966: {Animal cells}
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of isolation and identification of post-natal hemogenic endothelial cells. Further provided are substantially purified populations of post-natal hemogenic endothelial cells, compositions of post-natal hemogenic endothelial cells, and methods to utilize hemogenic endothelial cells to regenerate the hematopoietic system in a subject.

## Claims

### Claim 1

A method of isolating post-natal hemogenic endothelial cells (HECs), comprising isolating CD144+CD45+ cells from a post-natal subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said HECs are capable of generating hematopoietic cells following transplantation into a recipient.

### Claim 3 (depends on 1)

The method of claim 1, wherein said CD144+CD45+ cells are isolated from the liver, spleen, bone marrow, blood, umbilical cord, skin, kidney, muscle, or lung of said subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cells are isolated from the liver of said subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the isolated HECs are comprised in a substantially pure population of CD144+CD45+ post-natal cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein said isolation step further comprises selection of cells based on expression of at least one additional marker selected from CD180, chemokine C—X—C motif receptor 2 (CXCR2), chemokine C—X—C motif receptor 3 (CXCR3), chemokine C—X3-C motif receptor 1 (CX3CR1), chemokine C—C motif receptor 9 (CCR9), G protein-coupled receptor 141 (GPR141), G protein-coupled receptor 174 (GPR174), Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF9), integrin alpha L (ITGAL), integrin alpha X (ITGAX), and membrane-spanning 4-domain, subfamily A, member 6D (MS4A6D).

### Claim 7

A composition comprising a substantially pure population of CD144+CD45+ post-natal hemogenic endothelial cells (HECs).

### Claim 8 (depends on 7)

The composition of claim 7, wherein said HECs are autologous to a subject for whom administration of said composition is contemplated.

### Claim 9 (depends on 7)

The composition of claim 7, wherein said HECs are allogeneic to a subject for whom administration of said composition is contemplated.

### Claim 10 (depends on 7)

The composition of claim 7, wherein said composition comprises CD144+CD45+ post-natal HECs in admixture with a pharmaceutically acceptable carrier.

### Claim 11 (depends on 7)

The composition of claim 7, wherein said composition comprises CD144+CD45+ post-natal HECs in admixture with a culture medium.

### Claim 12 (depends on 7)

The composition of claim 7, wherein said composition comprises CD144+CD45+ post-natal HECs in admixture with a cryoprotective agent.

### Claim 13

A method of treatment for an immunodeficiency disorder, comprising administering a substantially pure population of CD144+CD45+ post-natal hemogenic endothelial cells to a subject in need thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said immunodeficiency disorder is selected from a T-cell deficiency, a B-cell deficiency, a combined T-cell/B-cell deficiency, an antibody deficiency, a complement deficiency, leukemia, lymphoma, anemia, neutropenia, lymphopenia, lupus, and Wiskott-Aldrich syndrome.

### Claim 15 (depends on 13)

The method of claim 13, wherein said immunodeficiency disorder results from administration of an immunosuppressive or cytotoxic agent.

### Claim 16 (depends on 13)

The method of claim 13, wherein said immunodeficiency disorder results from infection with human immunodeficiency virus (HIV) or hepatitis.

### Claim 17

A method of identifying hemogenic endothelial cells (HECs) in a post-natal subject, comprising identifying cells that are CD144+CD45+ in said subject.

### Claim 18 (depends on 17)

The method of claim 17, further comprising identifying expression of at least one additional marker selected from CD180, chemokine C—X—C motif receptor 2 (CXCR2), chemokine C—X—C motif receptor 3 (CXCR3), chemokine C—X3-C motif receptor 1 (CX3CR1), chemokine C—C motif receptor 9 (CCR9), G protein-coupled receptor 141 (GPR141), G protein-coupled receptor 174 (GPR174), Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF9), integrin alpha L (ITGAL), integrin alpha X (ITGAX), and membrane-spanning 4-domain, subfamily A, member 6D (MS4A6D).
